Indication of a role of plasminogen activator inhibitor type I in protecting murine fibrosarcoma cells against apoptosis

Thrombosis and Haemostasis

Volumn 94, Issue 4, 2005, Pages 859-866

  Rømer, Maria Unni ^a,b   Due, Anne Kirkebjerg ^a   Larsen, Jørgen Knud ^d   Hofland, Kenneth Francis ^b   Christensen, Ib Jarle ^c   Buhl Jensen, Peter ^b   Almholt, Kasper ^d   Nielsen, Ole Lerberg ^a   Brünner, Nils ^a   Lademann, Ulrik ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

^d NONE

Author keywords

Apoptosis; Murine fribrosarcoma cell lines; PAI I

Indexed keywords

AGAR; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANEUPLOIDY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; CELL PROTECTION; CELL TYPE; CONTROLLED STUDY; FIBROBLAST; FIBROSARCOMA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN FUNCTION; WESTERN BLOTTING; WILD TYPE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; FIBROBLASTS; FIBROSARCOMA; MALE; MICE; MICE, MUTANT STRAINS; MICE, NUDE; NEOPLASM TRANSPLANTATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; SOFT TISSUE NEOPLASMS;

EID: 27144539218     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-01-0011     Document Type: Article

References (36)

1. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: Recent advances and implication for prognosis and therapy. Cancer Metastasis Reviews 2003; 22: 205-22.
2. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92: 827-39.
3. Dano K, Romer J, Nielsen BS et al. Cancer invasion and tissue remodeling - cooperation of protease systems and cell types. Apmis 1999; 107: 120-7.
4. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000; 57: 25-40.
5. Hagedorn HG, Bachmeier BE, Nerlich AG. Synthesis and degradation of basement membranes and extracellular matrix and their regulation by TGF-beta in invasive carcinomas (Review). Int J Oncol 2001; 18: 669-81.
6. Rosenthal EL, Johnson TM, Allen ED et al. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells. Cancer Res 1998; 58: 5221-30.
7. Padro T, Mesters RM, Dankbar B et al. The catalytic domain of endogenous urokinase-type plasminogen activator is required for the mitogenic activity of platelet-derived and basic fibroblast growth factors in human vascular smooth muscle cells. J Cell Sci 2002; 115(Pt 9): 1961-71.
8. Bajou K, Noel A, Gerard RD et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998; 4: 923-8.
9. Bajou K, Masson V, Gerard RD et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin: Implications for antiangiogenic strategies. J Cell Biol 2001; 152: 777-84.
10. Kjoller L. The urokinase plasminogen activator receptor in the regulation of the actin cytoskeleton and cell motility. Biol Chem 2002; 383: 5-19.
11. Behrendt N, Ronne E, Dano K. The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface. Biol Chem Hoppe Seyler 1995; 376(5): 269-79.
12. Durand MK, Bodker JS, Christensen A et al. Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis. Thromb Haemost 2004; 91(3): 438-49.
13. Look MP, Foekens JA. Clinical relevance of the urokinase plasminogen activator system in breast cancer. Apmis 1999; 107: 150-9.
14. Schmitt M, Harbeck N, Thomssen C et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 1997; 78: 285-96.
15. Papadopoulou S, Scorilas A, Yotis J et al. Significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 (PAI-1) expression in human colorectal carcinomas. Tumour Biol 2002; 23: 170-8.
16. Sier CF, Vloedgraven HJ, Ganesh S et al. Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Gastroenterology 1994; 107: 1449-56.
17. Look MP, van Putten WL, Duffy MJ et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002; 94: 116-28.
18. Harbeck N, Kates RE, Gauger K et al. Urokinase-type plasminogen activator (uPA) and ist inhibitor PAI-1: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. Thromb Haemost 2004; 91: 450-6.
19. Stefansson S, McMahon GA, Petitclerc E et al. Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des 2003; 9: 1545-64.
20. Kwaan HC, Wang J, Svoboda K et al. Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis. Br J Cancer 2000; 82: 1702-8.
21. Chen Y, Kelm RJ, Jr., Budd RC et al. Inhibition of apoptosis and caspase-3 in vascular smooth muscle cells by plasminogen activator inhibitor type-1. J Cell Biochem 2004; 92: 178-88.
22. Carmeliet P, Kieckens L, Schoonjans L et al. Plasminogen-activator inhibitor-1 gene deficient mice .1. generation by homologous recombination and characterization. J Clin Invest 1993; 9: 2746-55.
23. Brunner N, Boysen B, Romer J et al. The nude mouse as an in vivo model for human breast cancer invasion and metastasis. Breast Cancer Res Treat 1993; 24(3): 257-64.
24. Laird PW, Zijderveld A, Linders K et al. Simplified mammalian DNA isolation procedure. Nucleic Acids Res 1991; 19: 4293.
25. Almholt K, Nielsen BS, Frandsen TL et al. Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice. Oncogene 2003; 22: 4389-97.
26. Vindelov LL, Christensen IJ. A review of techniques and results obtained in one laboratory by an integrated system of methods designed for routine clinical flow cytometric DNA analysis. Cytometry 1990; 11: 753-70.
27. Jensen PB, Christensen IJ, Sehested M et al. Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines. Br J Cancer 1993; 67: 311-20.
28. Bancroft JD. Theory and Practice of Histological Techniques. Stevens A., editor. [4th ed], 1-766. Hong Kong, Churchill Livingstone. Ref Type: Generic.
29. Goldenberg DM, Pavia RA. In vivo horizontal oncogenesis by a human tumor in nude mice. Proc Natl Acad Sci U S A 1982; 79: 2389-92.
30. Schrohl AS, Christensen IJ, Pedersen AN et al. Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer. Mol Cell Proteomics 2003; 2: 164-72.
31. Pappot H. The plasminogen activation system in lung cancer - with special reference to the prognostic role in "non-small cell lung cancer". APMIS Suppl 1999; 92: 1-29.
32. Bindal AK, Hammoud M, Shi WM et al. Prognostic significance of proteolytic enzymes in human brain tumors. J Neurooncol 1994; 22: 101-10.
33. Nozaki S, Endo Y, Kawashiri S et al. Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis. Oral Oncol 1998; 34: 58-62.
34. Bianchi E, Cohen RL, Dai A et al. Immunohistochemical localization of the plasminogen activator inhibitor-1 in breast cancer. Int J Cancer; 60: 597-603.
35. Gutierrez LS, Schulman A, Brito-Robinson T et al. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Research 2000; 60: 5839-47.
36. Nykjaer A, Conese M, Christensen EI et al. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J 1997; 16: 2610-20.